Krystal Biotech, Inc. (KRYS) - Form 8-K Summary
Business Context and Reporting Period
Krystal Biotech, Inc., a Delaware corporation, filed this Current Report on Form 8-K on February 17, 2026. The filing announces the Company's financial results for the quarter and full year ended December 31, 2025. The Company is listed on the Nasdaq Global Select Market under the symbol KRYS.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics for the reported period.
Material Changes
The filing text does not contain specific comparative data or descriptions of material changes versus prior periods. Investors must refer to the attached press release for year-over-year or quarter-over-quarter analysis.
Guidance, Outlook, and Risks
The filing text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These disclosures are contained within the referenced press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific revenue, net loss, and cash position figures for Q4 and FY 2025.
- Verify the Company's cash runway and burn rate as disclosed in the full financial statements.
- Confirm any updates to clinical trial milestones or regulatory approvals mentioned in the press release.
- Check for any new debt issuances or equity dilution events referenced in the full report.